Genetically Modified Cells TRIZ Cases
- Peptides Modulating T Cell Cytokine Production for Cancer Immunotherapy
Targeted peptides modulate T cell cytokine profiles to overcome chemotherapy resistance and reduce side effects in cancer treatment.
- iPSC Differentiation into CD34+ and NK Cells via Normoxia-Hypoxia Culture
Normoxia-hypoxia culture method accelerates iPSC differentiation into CD34+ cells and NK cells, resolving low yield bottlenecks.
- Non-viral episomal vectors for primate stem cell reprogramming
Episomal vectors deliver transcription factors to reprogram primate somatic cells, eliminating viral integration risks and genomic safety hazards.
- Bach2 Gene Modified B Cell Culture for Antibody Production
Increasing Bach2 expression in cultured B cells enables rapid generation of high affinity monoclonal antibodies without lengthy animal immunization periods.
- PD-L1 Binding Proteins for Solid Tumor Treatment
Secreted PD-L1 binding proteins from modified lymphocytes relieve the PD-1-PD-L1 interaction, enhancing anti-tumor immune response in solid tumors.
- High-Throughput ORF Screening for Transcription Factor Identification
Segmented ORF screening platforms identify ETV2 as an endothelial reprogramming driver, resolving the bottleneck of time-consuming trial-and-error discovery.
- Stem Cell Cloning via Gene-Induced Dedifferentiation
A stem cell cloning method uses gene-induced dedifferentiation to isolate uniform clones with high proliferation rates.
- Nuclear Reprogramming Using miRNA to Boost iPS Cell Yield
Combining specific microRNAs with reprogramming factors increases induced pluripotent stem cell yield while avoiding tumorigenic risks from c-Myc.
- Inducible Pluripotent Stem Cells for Universal Transplantation
A pluripotent stem cell engineered with inducible gene expression systems to dynamically control HLA presentation and mediate RNA interference.
- Stem Cell Induction via HMBPP Phosphate Treatment
Replacing zoledronic acid with HMBPP achieves complete J1/J2 gene rearrangement while maintaining high stem cell induction efficiency for immunotherapy.
- H19 and IG DMR Knockout in Androgenetic Stem Cells
Knocking out H19 and IG differentially methylated regions in androgenetic haploid embryonic stem cells to establish round spermatid-like characteristics.
- Skin Appendage-Inducible Cells via Transcription Factor Reprogramming
Introducing LEF1, DNP63A, GRHL2, TFAP2A, and SHH genes into somatic cells creates skin appendage-inducible cells for treating alopecia.
- iPS Cell Reprogramming Using DLX4, OCT3/4, and SOX2 Genes
Replacing c-MYC with DLX4, OCT3/4, and SOX2 genes eliminates tumor formation risk while maintaining high induction efficiency.
- WDR5 Interaction Modulation for Serum-Free Mesodermal Cell Derivation
Disrupting and re-establishing WDR5 binding reduces culture costs and variability while producing high-quality cardiac and hematopoietic organoids.
- Mammalian Cell Culture Media Without Serum
Selective breeding isolates mammalian cells thriving in defined media lacking serum and insulin, eliminating contamination risks and reducing production costs.
- Microbial Biocontainment via Nutrient Dependency and Recombinase Control
Nutrient dependency and recombinase systems reduce escape rates while maintaining microbial fitness for industrial scale-up.